Eli Lilly and Company (LLY) To Go Ex-Dividend on November 13th

Eli Lilly and Company (NYSE:LLY) announced a quarterly dividend on Monday, October 26th. Shareholders of record on Friday, November 13th will be given a dividend of $1.73 per share on Thursday, December 10th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th.

Eli Lilly and Company has raised its dividend payment by an average of 0.2% per year over the last three years and has increased its dividend annually for the last 11 consecutive years. Eli Lilly and Company has a payout ratio of 23.3% meaning its dividend is sufficiently covered by earnings. Research analysts expect Eli Lilly and Company to earn $47.23 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 14.7%.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,283.52 on Wednesday. Eli Lilly and Company has a twelve month low of $809.63 and a twelve month high of $1,321.21. The firm has a 50 day simple moving average of $1,191.27 and a 200-day simple moving average of $1,088.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same period last year, the business earned $6.31 earnings per share. The company’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 33.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LLY. UBS Group set a $1,376.00 target price on Eli Lilly and Company in a report on Friday, August 7th. Citigroup raised their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,413.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Finally, Guggenheim raised their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,320.25.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.